Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


Predictors of recovery of ovarian function during aromatase inhibitor therapy.

Henry NL, Xia R, Banerjee M, Gersch C, McConnell D, Giacherio D, Schott AF, Pearlman M, Stearns V, Partridge AH, Hayes DF.

Ann Oncol. 2013 Aug;24(8):2011-6. doi: 10.1093/annonc/mdt149. Epub 2013 Apr 23.


Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.

Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, Vukelja SJ, Holmes FA, Reddy PK, Asmar L, Wang Y, Fox PS, Peck SR, O'Shaughnessy J.

J Clin Oncol. 2016 May 10;34(14):1594-600. doi: 10.1200/JCO.2015.62.2985. Epub 2016 Feb 16.


Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.

Dieudonné AS, Vandenberghe J, Geerts I, Billen J, Paridaens R, Wildiers H, Neven P.

Menopause. 2011 Jul;18(7):821-4. doi: 10.1097/gme.0b013e318204af88.


Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.


Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.

Guerrero A, Gavilá J, Folkerd E, Ortiz B, Martínez F, García A, Climent MA, Guillem V, Ruíz A.

Ann Oncol. 2013 Mar;24(3):674-9. doi: 10.1093/annonc/mds464. Epub 2012 Oct 28.


Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

Smith IE, Dowsett M, Yap YS, Walsh G, Lønning PE, Santen RJ, Hayes D.

J Clin Oncol. 2006 Jun 1;24(16):2444-7.


Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.

Tiong V, Rozita AM, Taib NA, Yip CH, Ng CH.

World J Surg. 2014 Sep;38(9):2288-96. doi: 10.1007/s00268-014-2542-y.


Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.

Nagao T, Kira M, Takahashi M, Honda J, Hirose T, Tangoku A, Zembutsu H, Nakamura Y, Sasa M.

World J Surg Oncol. 2009 Nov 12;7:88. doi: 10.1186/1477-7819-7-88.


Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.


Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.


A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.

N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].


Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG.

Lancet. 2005 Aug 6-12;366(9484):455-62.


Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.


Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M.

Lancet Oncol. 2008 Jan;9(1):45-53.


Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.

Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P.

Ann Oncol. 2006 Jun;17 Suppl 7:vii10-4.


Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.


Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.

Supplemental Content

Support Center